AMS vs BLCO vs ATRC vs IART

For growth investors, American Shared Hospital Services (AMS) is the stronger pick with 32.

9% revenue growth year-over-year, versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). American Shared Hospital Services (AMS) offers the better valuation at 6. 1x trailing P/E, making it the more compelling value choice. Analysts rate AtriCure, Inc. (ATRC) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Integra LifeSciences Holdings Corporation is actually cheaper at 5.

8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Bausch + Lomb Corporation (BLCO) delivered a total return of -20.

5%, compared to -81. 7% for Integra LifeSciences Holdings Corporation (IART). Over 10 years, the gap is even starker: ATRC returned +95. 1% versus IART's -63. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), American Shared Hospital Services (AMS) is the lower-risk stock at -0.

02β versus Integra LifeSciences Holdings Corporation's 2. 34β — meaning IART is approximately -14990% more volatile than AMS relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 195% for Integra LifeSciences Holdings Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), American Shared Hospital Services (AMS) is pulling ahead at 32.

9% versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). On earnings-per-share growth, the picture is similar: American Shared Hospital Services grew EPS 245. 9% year-over-year, compared to -73. 6% for Integra LifeSciences Holdings Corporation. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

American Shared Hospital Services (AMS) is the more profitable company, earning 7.

7% net margin versus -31. 6% for Integra LifeSciences Holdings Corporation — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IART leads at 4. 2% versus -9. 9% for AMS. At the gross margin level — before operating expenses — ATRC leads at 74. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Integra LifeSciences Holdings Corporation (IART) trades at 5.

8x forward P/E versus 370. 7x for AtriCure, Inc. — 364. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 82. 3% to $50. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, American Shared Hospital Services (AMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

02)). Integra LifeSciences Holdings Corporation (IART) carries a higher beta of 2. 34 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMS: -4. 7%, IART: -63. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AMS is a small-cap high-growth stock; BLCO is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock; IART is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.